These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 1396833

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
    Lancet; 1989 Apr 22; 1(8643):863-8. PubMed ID: 2564949
    [Abstract] [Full Text] [Related]

  • 4. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. The PRIMI Trial Study Group.
    Schofer J, Lins M, Mathey DG, Sheehan FH.
    Eur Heart J; 1993 Jul 22; 14(7):958-63. PubMed ID: 8375422
    [Abstract] [Full Text] [Related]

  • 5. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE, Brower RW, Collen D, van Es GA, Lubsen J, Serruys PW, Simoons ML, Verstraete M.
    J Am Coll Cardiol; 1989 Sep 22; 14(3):581-8. PubMed ID: 2504798
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E.
    Am J Cardiol; 1991 Dec 15; 68(17):1564-9. PubMed ID: 1746455
    [Abstract] [Full Text] [Related]

  • 8. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R, Carlsson J, Seifried E, Pfarr E, Smolarz A, Neuhaus KL, Tebbe U.
    Int J Cardiol; 1998 Jun 01; 65(1):57-63. PubMed ID: 9699932
    [Abstract] [Full Text] [Related]

  • 9. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
    Salvioni A, Perego GB, Marenzi G, Lauri G, Giraldi F, Grazi S, Guazzi MD.
    Eur Heart J; 1996 Feb 01; 17(2):230-6. PubMed ID: 8732376
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW, Cohen AF, Hopkins GR, Beier H, Günzler WA, van der Wouw PA.
    Thromb Haemost; 1994 Nov 01; 72(5):740-4. PubMed ID: 7534946
    [Abstract] [Full Text] [Related]

  • 13. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
    Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML.
    J Am Coll Cardiol; 1988 Jan 01; 11(1):1-11. PubMed ID: 3121710
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
    Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennell W, Betriu A, Ruda M, Mlczoch J.
    J Am Coll Cardiol; 1998 Mar 01; 31(3):487-93. PubMed ID: 9502624
    [Abstract] [Full Text] [Related]

  • 15. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
    Grines CL, Nissen SE, Booth DC, Branco MC, Gurley JC, Bennett KA, DeMaria AN.
    J Am Coll Cardiol; 1989 Sep 01; 14(3):573-80. PubMed ID: 2504797
    [Abstract] [Full Text] [Related]

  • 16. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ.
    J Am Coll Cardiol; 1992 Mar 01; 19(3):482-9. PubMed ID: 1537998
    [Abstract] [Full Text] [Related]

  • 17. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES, Cregeen RJ.
    Drugs; 1987 Mar 01; 33 Suppl 3():298-311. PubMed ID: 3315612
    [Abstract] [Full Text] [Related]

  • 18. Bleeding after thrombolysis in acute myocardial infarction.
    Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W.
    Eur Heart J; 1989 Jan 01; 10(1):16-23. PubMed ID: 2702962
    [Abstract] [Full Text] [Related]

  • 19. Clinical profile of saruplase: angiographic findings.
    Meyer J.
    Int J Clin Pract Suppl; 1998 Nov 01; 99():9-15. PubMed ID: 10344035
    [Abstract] [Full Text] [Related]

  • 20. Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.
    Spiecker M, Windeler J, Vermeer F, Michels R, Seabra-Gomes R, vom Dahl J, Kerber S, Verheugt FW, Westerhof PW, Bär FW, Nixdorff U, Barth H, Hopkins GR, von Fisenne MJ, Meyer J.
    Am Heart J; 1999 Sep 01; 138(3 Pt 1):518-24. PubMed ID: 10467203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.